3.1. IL-22 overexpression or Vit D supplementation does not protect mice from weight loss
In this project, mucositis was induced by intraperitoneal injections of methotrexate on days -1 and 0. IL-22 overexpression group received IL-22 plasmids via hydrodynamic gene delivery on day -2 as previously described.15 In our previous studies such injections were shown to result in durable systemic IL-22 expression compared with costly recombinant protein injections.19 Vit D injection was initiated on day -5 and mice received daily injections until termination of the experiment. To assess the impact of Vit D injections and IL-22 overexpression weight loss was recorded daily (Fig 1). Either treatment did not affect wasting disease post methotrexate administration suggesting that these treatments may not have impacted circulatory factors contributing to weight loss.